Danazol therapy for the anemia of myelofibrosis: assessment of efficacy with current criteria of response and long-term results. (Q33423956)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26122869 AND SRC:MED&resulttype=core&format=json

18 February 2020

title

Danazol therapy for the anemia of myelofibrosis: assessment of efficacy with current criteria of response and long-term results (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26122869 AND SRC:MED&resulttype=core&format=json

18 February 2020

1 reference

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26122869 AND SRC:MED&resulttype=core&format=json

Juan Carlos Hernandez-Boluda

18 February 2020

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26122869 AND SRC:MED&resulttype=core&format=json

18 February 2020

author name string

Ignacio M Isola

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26122869 AND SRC:MED&resulttype=core&format=json

18 February 2020

Alberto Alvarez-Larrán

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26122869 AND SRC:MED&resulttype=core&format=json

18 February 2020

Juan-Gonzalo Correa

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26122869 AND SRC:MED&resulttype=core&format=json

18 February 2020

Arturo Pereira

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26122869 AND SRC:MED&resulttype=core&format=json

18 February 2020

publication date

28 June 2015

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26122869 AND SRC:MED&resulttype=core&format=json

18 February 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26122869 AND SRC:MED&resulttype=core&format=json

18 February 2020

volume

94

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26122869 AND SRC:MED&resulttype=core&format=json

18 February 2020

issue

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26122869 AND SRC:MED&resulttype=core&format=json

18 February 2020

page(s)

1791-1796

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26122869 AND SRC:MED&resulttype=core&format=json

How I treat myelofibrosis

18 February 2020

cites work

1 reference

https://api.crossref.org/works/10.1007/S00277-015-2435-7

Induction of B7-H6, a ligand for the natural killer cell-activating receptor NKp30, in inflammatory conditions

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00277-015-2435-7

Revised response criteria for myelofibrosis: International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) and European LeukemiaNet (ELN) consensus report

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00277-015-2435-7

Efficacy and tolerability of danazol as a treatment for the anaemia of myelofibrosis with myeloid metaplasia: long-term results in 30 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00277-015-2435-7

Proposals and rationale for revision of the World Health Organization diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis: recommendations from an ad hoc international expert panel

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00277-015-2435-7

Lack of a relationship between the common 8q24 variant rs6983267 and risk of chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00277-015-2435-7

Pathogenesis and management of idiopathic myelofibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00277-015-2435-7

Efficacy and tolerability of hydroxyurea in the treatment of the hyperproliferative manifestations of myelofibrosis: results in 40 patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00277-015-2435-7

JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00277-015-2435-7

Erythropoietin treatment of the anaemia of myelofibrosis with myeloid metaplasia: results in 20 patients and review of the literature.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00277-015-2435-7

Recombinant human erythropoietin for the treatment of anaemia in patients with chronic idiopathic myelofibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00277-015-2435-7

Erythropoiesis stimulating agents have limited therapeutic activity in transfusion-dependent patients with primary myelofibrosis regardless of serum erythropoietin level

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00277-015-2435-7

A phase 2 trial of combination low-dose thalidomide and prednisone for the treatment of myelofibrosis with myeloid metaplasia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00277-015-2435-7

Lenalidomide and prednisone for myelofibrosis: Eastern Cooperative Oncology Group (ECOG) phase 2 trial E4903.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00277-015-2435-7

Lenalidomide plus prednisone results in durable clinical, histopathologic, and molecular responses in patients with myelofibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00277-015-2435-7

Oxymetholone treatment in myelofibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00277-015-2435-7

Pomalidomide is active in the treatment of anemia associated with myelofibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00277-015-2435-7

10.1007/S00277-015-2435-7

21 January 2018

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26122869 AND SRC:MED&resulttype=core&format=json

18 February 2020

1 reference